申请人:Merck & Co., Inc.
公开号:US06387893B1
公开(公告)日:2002-05-14
Spirotricyclic azacycloalkyl compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds is also described. One application of these compounds, which are alpha 1a adrenergic receptor antagonists, is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.
本文披露了螺环三环氮杂环烷基化合物及其药用盐。还描述了这些化合物的合成方法。这些化合物的一个应用是作为α1a肾上腺素能受体拮抗剂,用于治疗良性前列腺增生症。这些化合物在选择性上能够放松富含α1a受体亚型的平滑肌组织,而不会同时引起低血压。这样的组织包括尿道内衬。因此,这些化合物的一个用途是为患有良性前列腺增生症的男性提供急性缓解,使尿液流动更加顺畅。这些化合物的另一个用途是与人类5α-还原酶抑制剂化合物结合,从而实现对良性前列腺增生症的急性和慢性缓解效果。